Milestone Pharmaceuticals (MIST) has released an update.
Milestone Pharmaceuticals reveals encouraging results from a Phase 3 study, showing that their investigational drug etripamil enables patients to self-manage recurrent paroxysmal supraventricular tachycardia (PSVT). The study, which was presented at The American College of Cardiology meeting and published in the Journal of the American College of Cardiology, found that etripamil effectively restored sinus rhythm with a median time of 17 minutes and had a well-tolerated safety profile. These findings suggest etripamil, as a self-administered nasal spray, could revolutionize the acute treatment of PSVT.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
